Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara A Burtness

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Cancer|March 22, 2017
The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinomaYi An, Henry S Park, Jacqueline R Kelly, et al.
Head & Neck|June 28, 2013
Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancerCarolyn Y Fang, Brian L Egleston, John A Ridge, et al.
Cancer Biology & Therapy|August 13, 2002
Phase I study of perillyl alcohol in patients with refractory malignanciesJohn R Murren, Giuseppe Pizzorno, Susan A DiStasio, et al.
JAMA Oncology|October 14, 2016
A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell CarcinomaZain A Husain, Tiange Chen, Christopher D Corso, et al.
Cancer|March 15, 2006
Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarrayGina G Chung, Harry H Yoon, Maciej P Zerkowski, et al.
Nature Communications|November 28, 2017
NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosisSuraj Peri, Evgeny Izumchenko, Adrian D Schubert, et al.
The Oncologist|April 27, 2023
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN TrialShannon Stockton, Paul Catalano, Steven J Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell CarcinomaBenjamin H Kann, Daniel F Hicks, Sam Payabvash, et al.
American Journal of Clinical Oncology|May 12, 2010
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinomaIgor A Astsaturov, Neal J Meropol, R Katherine Alpaugh, et al.
Breast Cancer Research and Treatment|October 20, 2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancerMaysa M Abu-Khalaf, Vinni Juneja, Gina G Chung, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Cancer|March 22, 2017
The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinomaYi An, Henry S Park, Jacqueline R Kelly, et al.
Head & Neck|June 28, 2013
Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancerCarolyn Y Fang, Brian L Egleston, John A Ridge, et al.
Cancer Biology & Therapy|August 13, 2002
Phase I study of perillyl alcohol in patients with refractory malignanciesJohn R Murren, Giuseppe Pizzorno, Susan A DiStasio, et al.
JAMA Oncology|October 14, 2016
A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell CarcinomaZain A Husain, Tiange Chen, Christopher D Corso, et al.
Cancer|March 15, 2006
Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarrayGina G Chung, Harry H Yoon, Maciej P Zerkowski, et al.
Nature Communications|November 28, 2017
NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosisSuraj Peri, Evgeny Izumchenko, Adrian D Schubert, et al.
The Oncologist|April 27, 2023
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN TrialShannon Stockton, Paul Catalano, Steven J Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell CarcinomaBenjamin H Kann, Daniel F Hicks, Sam Payabvash, et al.
American Journal of Clinical Oncology|May 12, 2010
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinomaIgor A Astsaturov, Neal J Meropol, R Katherine Alpaugh, et al.
Breast Cancer Research and Treatment|October 20, 2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancerMaysa M Abu-Khalaf, Vinni Juneja, Gina G Chung, et al.
Pageof 8